- Kintor Pharmaceutical: KX-826, a New Name in Hair Loss Research KX-826 (pyrilutamide) is an experimental topical androgen receptor blocker from Kintor Pharmaceutical. It is not approved as a medicine anywhere; the company reports that its China Phase III trial met its primary endpoint at 24 weeks, but the trial data has been released through corporate announcements rather than peer-reviewed journals and long-term safety is unknown.
glaucoma medication with hair follicle stimulant effects
glycoprotein that inhibits TGF-β and promotes hair growth by antagonizing activin
herb and oil thought to stimulate skin and hair
signaling protein that, when suppressed, may grow hair by reducing inflammation and stem cell loss
the gold standard retinoid in dermatology that's also helpful for hair regrowth alongside Minoxidil
- Can pyrilutamide be used by both men and women, or only in specific cases? Pyrilutamide (KX-826) is an investigational topical anti-androgen that has been trialled in both men and women, but it is not approved for hair loss anywhere; the company reports that its China Phase III trial in men met its primary endpoint, but the data come from sponsor announcements rather than peer-reviewed journals, and long-term safety is unknown.